7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series
| Autor: | Gerry Oster, Derek Weycker, David R. Strutton, Jerome O. Klein, Stephen I. Pelton, Vincent Ciuryla |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
medicine.medical_specialty Heptavalent Pneumococcal Conjugate Vaccine Booster dose Pneumococcal conjugate vaccine Cohort Studies Pneumococcal Vaccines Internal medicine Ambulatory Care Medicine Humans Intensive care medicine Respiratory Tract Infections Retrospective Studies General Veterinary General Immunology and Microbiology Respiratory tract infections business.industry Incidence Vaccination Public Health Environmental and Occupational Health Infant Newborn Infant medicine.disease Hospitalization Regimen Pneumococcal infections Infectious Diseases Propensity score matching Insurance Health Reimbursement Molecular Medicine Female business medicine.drug |
| Zdroj: | Vaccine. 28(6) |
| ISSN: | 1873-2518 |
| Popis: | Background Immunogenicity studies suggest antibody responses from a 7-valent pneumococcal conjugate vaccine (PCV7) regimen consisting of 2 doses in the primary series are less immunogenic, for at least several vaccine serotypes, compared with a regimen consisting of 3 doses; evidence of effectiveness for prevention of invasive pneumococcal disease for both regimens is available but comparative data are lacking for prevention of lower respiratory tract diseases (LRTD). Methods We compared rates of LRTD between children who were born in 2002 and received 2 versus 3 PCV7 doses in the primary series, both before and after receipt of the booster dose, using a retrospective matched-cohort design and health insurance claims data. Two-dose and 3-dose children were matched (1:1) using propensity scoring. Cumulative rates of hospital admissions and outpatient visits for LRTD were tallied during the post-primary/pre-booster period and the post-booster period (to age 3 years), respectively. Results During the post-primary/pre-booster period, 3-dose children (n = 3293) had 7.8 (95% CI: 0.8 to 14.8) fewer LRTD-related hospital admissions (per 1000 children) and 57 (95% CI: −6 to 128) fewer LRTD-related outpatient visits (per 1000 children) than matched 2-dose subjects (n = 3293). During the post-booster period, the numbers of LRTD-related hospital admissions and outpatient visits did not differ significantly between 3-dose and 2-dose children. Conclusions Our findings suggest that a 2-dose PCV7 primary series, while conferring savings from reduced vaccine costs in comparison with a 3-dose primary series, also may confer less protection against LRTD in the first year of life, at least during the period soon after the vaccine is introduced. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect